Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking
AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited tre
The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o
AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl